<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02905760</url>
  </required_header>
  <id_info>
    <org_study_id>P150801</org_study_id>
    <nct_id>NCT02905760</nct_id>
  </id_info>
  <brief_title>Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction</brief_title>
  <acronym>FAMIE</acronym>
  <official_title>Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction With Right Ventricular Extension: A Multicentric Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Right ventricular necrosis increases patient in hospital mortality and can be observed in
      20-50% of patients admitted for during acute myocardial infarction. Current guidelines
      recommend managing cardiogenic shock related to right ventricular necrosis by optimizing RV
      load using fluid expansion and if insufficient adding inotropic support. However, several
      experimental studies reported a potential deleterious effect of right ventricular dilation
      related to fluid expansion because right and left ventricular interaction decreases stroke
      volume and cardiac output. Consistently with these finding, a study on a small patient sample
      conducted at Henri Mondor Hospital demonstrates the safety and efficiency of furosemide in
      patients with right ventricular necrosis.

      The present study is a phase 3, interventional, prospective, randomized, multicenter,
      double-blind analysis by intention to treat.

      The main objective is to demonstrate improved hemodynamic parameters in the short term in
      patients admitted for acute myocardial infarction with extension RV treated with furosemide.

      The primary endpoint is compare the change in cardiac output in patients admitted and treated
      by either fluid expansion or furosemide.

      The study population will consist in 88 patients and the duration of subjects' participation
      will be one month.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in cardiac output (measured by Doppler method) defined by an increase of more than 10% 24 hours after administration of the treatment in patients admitted and treated by either fluid expansion or furosemide.</measure>
    <time_frame>At Hour 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-hospital mortality</measure>
    <time_frame>an average of 10 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of inotropic support</measure>
    <time_frame>an average of 10 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hemodynamic instability requiring fluid expansion</measure>
    <time_frame>an average of 10 days after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine output</measure>
    <time_frame>Hour 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration of hospitalization in intensive care</measure>
    <time_frame>an average of month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations for cardiovascular reason one month after acute myocardial infarction</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One month mortality</measure>
    <time_frame>month 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Acute Myocardial Infarction With Right Ventricular Extension</condition>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Furosemide and Placebo filling (Glucose 5%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluid expansion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo furosemide (Glucose 5%) and Vascular filling
The vascular filling is the gold standard in the treatment of acute myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like &quot;penicillin&quot; of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)</description>
    <arm_group_label>Furosemide</arm_group_label>
    <other_name>Diuretics, LASILIX.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo filling</intervention_name>
    <description>Placebo filling: Glucose 5%, 500mL infused over 30 minutes.</description>
    <arm_group_label>Furosemide</arm_group_label>
    <other_name>G5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo furosemide</intervention_name>
    <description>Placebo furosemide: glucose 5% for injection reconditioned glass bottle like &quot;penicillin&quot; of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial).</description>
    <arm_group_label>Fluid expansion</arm_group_label>
    <other_name>G5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vascular filling</intervention_name>
    <description>Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.</description>
    <arm_group_label>Fluid expansion</arm_group_label>
    <other_name>Fluid expansion, Sodium Chloride NaCl 0.9%.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Age &gt;18 years

          -  Inferior acute myocardial infarction (≤J + 7)

          -  Right ventricular extension defined by one following echocardiographic criteria:

               -  Dilatation of the right ventricle (RV/LV area&gt; 0.9)

               -  RV dysfunction defined by TAPSE &lt;16mm or S velocity &lt;10cm.s-1

               -  Akinesia or hypokinesia of two contiguous segments of the right ventricle

               -  Decrease of pitch on lung failure flow &lt;150ms

          -  Inferior vena cava dilatation (≥20mm) and non-compliant (changes &lt;50%) associated with
             one hemodynamic instability criteria:

               -  Oliguria (diuresis &lt;800mL/24h or 0.5mL/kg/min)

               -  Systolic blood pressure &lt;100mmHg

               -  Oxygen saturation &lt;91% on room air

               -  Bradycardia (heart rate &lt;60/min, not valid for patients on beta-blockers).

          -  Informed consent for study participation signed.

        Exclusion Criteria

          -  Minor and pregnant woman

          -  Mechanical complications of myocardial infarct

          -  Patients who received&gt; 40mg diuretic /day during the last 15 days

          -  Hypersensitivity to furosemide or any of its excipients

          -  Aortic stenosis (area &lt;1 cm² or mean gradient&gt; 40mmHg), mitral or aortic regurgitation
             grade ≥3

          -  Catecholamine support for left ventricular failure with left ventricular ejection
             fraction &lt;35%

          -  Renal impairment defined by a serum creatinine&gt; 200μmol / mL

          -  Sodium and water retention

          -  Urinary tract obstruction

          -  Hypovolemia or dehydration

          -  Severe hypokalemia (K + &lt;3 mmol / L)

          -  Severe hyponatremia (Na + &lt;125 mmol / L)

          -  Hepatitis ongoing, liver failure or hepatic encephalopathy

          -  No affiliation to a social security scheme or other social protection scheme

          -  Private Patient of liberty or under legal protection (guardianship)

          -  Inability or refusal to understand or refusal to sign the informed consent from study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal Lim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal Lim, MD, PhD</last_name>
    <phone>(0)1 49 81 45 84</phone>
    <phone_ext>+33</phone_ext>
    <email>lim.pascal.hmn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ludivine Brouard, CRA</last_name>
    <phone>(0)1 49 81 37 53</phone>
    <phone_ext>+33</phone_ext>
    <email>ludivine.brouard@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2016</study_first_submitted>
  <study_first_submitted_qc>September 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2016</study_first_posted>
  <last_update_submitted>September 16, 2016</last_update_submitted>
  <last_update_submitted_qc>September 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocardial Infarction</keyword>
  <keyword>Right ventricular infarction</keyword>
  <keyword>Diuretic</keyword>
  <keyword>Fluid Expansion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

